{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:39Z","timestamp":1790399859208,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T00:00:00Z","timestamp":1418169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00213-014-3813-x","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T22:58:52Z","timestamp":1418165932000},"page":"1859-1866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey"],"prefix":"10.1007","volume":"232","author":[{"given":"Joshua D.","family":"Vardigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Dancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmyJo","family":"Koser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Kuduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Renger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Uslaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,10]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"A Atri","year":"2008","unstructured":"Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209\u2013221","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3813_CR2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.neuropharm.2011.08.023","volume":"61","author":"SJ Bartko","year":"2011","unstructured":"Bartko SJ, Romberg C, White B, Wess J, Bussey TJ, Saksida LM (2011) Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. Neuropharmacology 61:1366\u20131378","journal-title":"Neuropharmacology"},{"key":"3813_CR3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408\u2013414","journal-title":"Science"},{"key":"3813_CR4","doi-asserted-by":"crossref","first-page":"C131","DOI":"10.1152\/ajpcell.1996.270.1.C131","volume":"270","author":"P Beguin","year":"1996","unstructured":"Beguin P, Beggah A, Cotecchia S, Geering K (1996) Adrenergic, dopaminergic, and muscarinic receptor stimulation leads to PKA phosphorylation of Na-K-ATPase. Am J Physiol 270:C131\u2013C137","journal-title":"Am J Physiol"},{"key":"3813_CR5","doi-asserted-by":"crossref","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev CD005593","DOI":"10.1002\/14651858.CD005593"},{"key":"3813_CR6","doi-asserted-by":"crossref","unstructured":"Birks J, Flicker L (2006) Donepezil for mild cognitive impairment. Cochrane Database Syst Rev CD006104","DOI":"10.1002\/14651858.CD006104"},{"key":"3813_CR7","doi-asserted-by":"crossref","unstructured":"Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev CD001190","DOI":"10.1002\/14651858.CD001190.pub2"},{"key":"3813_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997a) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465\u2013473","journal-title":"Arch Neurol"},{"issue":"Suppl 4","key":"3813_CR9","first-page":"S16","volume":"11","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM (1997b) The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 11(Suppl 4):S16\u2013S22","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3813_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0028-3932(88)90004-8","volume":"26","author":"P Broks","year":"1988","unstructured":"Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26:685\u2013700","journal-title":"Neuropsychologia"},{"key":"3813_CR11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/cns.12076","volume":"19","author":"JL Cummings","year":"2013","unstructured":"Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P (2013) High-dose donepezil (23 mg\/day) for the treatment of moderate and severe Alzheimer\u2019s disease: drug profile and clinical guidelines. CNS Neurosci Ther 19:294\u2013301","journal-title":"CNS Neurosci Ther"},{"key":"3813_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11539810-000000000-00000","volume":"25","author":"J Delrieu","year":"2011","unstructured":"Delrieu J, Piau A, Caillaud C, Voisin T, Vellas B (2011) Managing cognitive dysfunction through the continuum of Alzheimer\u2019s disease: role of pharmacotherapy. CNS Drugs 25:213\u2013226","journal-title":"CNS Drugs"},{"key":"3813_CR13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/0735-7044.103.3.526","volume":"103","author":"A Diamond","year":"1989","unstructured":"Diamond A, Zola-Morgan S, Squire LR (1989) Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants. Behav Neurosci 103:526\u2013537","journal-title":"Behav Neurosci"},{"key":"3813_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","volume":"30","author":"DA Drachman","year":"1974","unstructured":"Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113\u2013121","journal-title":"Arch Neurol"},{"key":"3813_CR15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/026988110001400301","volume":"14","author":"S Dronfield","year":"2000","unstructured":"Dronfield S, Egan K, Marsden CA, Green AR (2000) Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 14:275\u2013279","journal-title":"J Psychopharmacol"},{"key":"3813_CR16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0079-6468(05)43004-0","volume":"43","author":"RM Eglen","year":"2005","unstructured":"Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105\u2013136","journal-title":"Prog Med Chem"},{"key":"3813_CR17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1096\/fasebj.9.8.7768353","volume":"9","author":"CC Felder","year":"1995","unstructured":"Felder CC (1995) Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 9:619\u2013625","journal-title":"FASEB J"},{"key":"3813_CR18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s002130050672","volume":"138","author":"JP Hatcher","year":"1998","unstructured":"Hatcher JP, Loudon JM, Hagan JJ, Clark MS (1998) Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Psychopharmacology (Berl) 138:275\u2013282","journal-title":"Psychopharmacology (Berl)"},{"key":"3813_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","volume":"605","author":"JN Heinrich","year":"2009","unstructured":"Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC (2009) Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605:53\u201356","journal-title":"Eur J Pharmacol"},{"key":"3813_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2010.538083","volume":"12","author":"R Ihl","year":"2011","unstructured":"Ihl R, Frolich L, Winblad B, Schneider L, Burns A, Moller HJ (2011) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer\u2019s disease and other dementias. World J Biol Psychiatry 12:2\u201332","journal-title":"World J Biol Psychiatry"},{"key":"3813_CR21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0016-5085(90)91022-X","volume":"99","author":"Y Iwanaga","year":"1990","unstructured":"Iwanaga Y, Miyashita N, Morikawa K, Mizumoto A, Kondo Y, Itoh Z (1990) A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology 99:401\u2013408","journal-title":"Gastroenterology"},{"key":"3813_CR22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0306-4522(98)00481-3","volume":"90","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Taylor JR, Elsworth JD, Redmond DE Jr, Roth RH (1999a) Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 90:823\u2013832","journal-title":"Neuroscience"},{"key":"3813_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s002130050865","volume":"142","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Taylor JR, Redmond DE Jr, Elsworth JD, Youngren KD, Roth RH (1999b) Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval\/detour deficits in monkeys. Psychopharmacology (Berl) 142:78\u201384","journal-title":"Psychopharmacology (Berl)"},{"key":"3813_CR24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1212\/CPJ.0b013e318278bebd","volume":"2","author":"DS Knopman","year":"2012","unstructured":"Knopman DS (2012) Donepezil 23 mg: an empty suit. Neurol Clin Pract 2:352\u2013355","journal-title":"Neurol Clin Pract"},{"key":"3813_CR25","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1021\/jm200400m","volume":"54","author":"SD Kuduk","year":"2011","unstructured":"Kuduk SD, Chang RK, Di Marco CN, Pitts DR, Greshock TJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Hartman GD, Bilodeau MT, Ray WJ (2011) Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. J Med Chem 54:4773\u20134780","journal-title":"J Med Chem"},{"key":"3813_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","volume":"52","author":"AI Levey","year":"1993","unstructured":"Levey AI (1993) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52:441\u2013448","journal-title":"Life Sci"},{"key":"3813_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2003.11.080","volume":"486","author":"DR Liston","year":"2004","unstructured":"Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF (2004) Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer\u2019s disease. Eur J Pharmacol 486:9\u201317","journal-title":"Eur J Pharmacol"},{"key":"3813_CR28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000255578","volume":"28","author":"IA Lockhart","year":"2009","unstructured":"Lockhart IA, Mitchell SA, Kelly S (2009) Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer\u2019s disease: systematic review of the \u2018real-world\u2019 evidence. Dement Geriatr Cogn Disord 28:389\u2013403","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3813_CR29","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.1073\/pnas.95.19.11465","volume":"95","author":"MJ Marino","year":"1998","unstructured":"Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A 95:11465\u201311470","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3813_CR30","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.lfs.2004.05.034","volume":"75","author":"M Matsui","year":"2004","unstructured":"Matsui M, Yamada S, Oki T, Manabe T, Taketo MM, Ehlert FJ (2004) Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci 75:2971\u20132981","journal-title":"Life Sci"},{"key":"3813_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9:159\u2013186","journal-title":"CNS Drug Rev"},{"key":"3813_CR32","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1152\/jn.1992.68.6.2264","volume":"68","author":"W Muller","year":"1992","unstructured":"Muller W, Petrozzino JJ, Griffith LC, Danho W, Connor JA (1992) Specific involvement of Ca(2+)-calmodulin kinase II in cholinergic modulation of neuronal responsiveness. J Neurophysiol 68:2264\u20132269","journal-title":"J Neurophysiol"},{"issue":"566\u201374","key":"3813_CR33","first-page":"e256","volume":"24","author":"K Nagahama","year":"2012","unstructured":"Nagahama K, Matsunaga Y, Kawachi M, Ito K, Tanaka T, Hori Y, Oka H, Takei M (2012) Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulates gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil 24(566\u201374):e256","journal-title":"Neurogastroenterol Motil"},{"key":"3813_CR34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/334434a0","volume":"334","author":"EG Peralta","year":"1988","unstructured":"Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ (1988) Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 334:434\u2013437","journal-title":"Nature"},{"key":"3813_CR35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jalz.2012.01.002","volume":"9","author":"SD Rountree","year":"2013","unstructured":"Rountree SD, Atri A, Lopez OL, Doody RS (2013) Effectiveness of antidementia drugs in delaying Alzheimer\u2019s disease progression. Alzheimers Dement 9:338\u2013345","journal-title":"Alzheimers Dement"},{"key":"3813_CR36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","volume":"113","author":"R Schliebs","year":"2006","unstructured":"Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer\u2019s disease. J Neural Transm 113:1625\u20131644","journal-title":"J Neural Transm"},{"key":"3813_CR37","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(04)16533-1","volume":"363","author":"LS Schneider","year":"2004","unstructured":"Schneider LS (2004) AD2000: donepezil in Alzheimer\u2019s disease. Lancet 363:2100\u20132101","journal-title":"Lancet"},{"key":"3813_CR38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMe1200429","volume":"366","author":"LS Schneider","year":"2012","unstructured":"Schneider LS (2012) Discontinuing donepezil or starting memantine for Alzheimer\u2019s disease. N Engl J Med 366:957\u2013959","journal-title":"N Engl J Med"},{"key":"3813_CR39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0024-3205(95)00023-Y","volume":"56","author":"AJ Sedman","year":"1995","unstructured":"Sedman AJ, Bockbrader H, Schwarz RD (1995) Preclinical and phase 1 clinical characterization of CI-979\/RU35926, a novel muscarinic agonist for the treatment of Alzheimer\u2019s disease. Life Sci 56:877\u2013882","journal-title":"Life Sci"},{"key":"3813_CR40","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","volume":"29","author":"JK Shirey","year":"2009","unstructured":"Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29:14271\u201314286","journal-title":"J Neurosci"},{"key":"3813_CR41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/mol.108.054452","volume":"76","author":"DA Sykes","year":"2009","unstructured":"Sykes DA, Dowling MR, Charlton SJ (2009) Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76:543\u2013551","journal-title":"Mol Pharmacol"},{"issue":"Pt 3","key":"3813_CR42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/113.3.617","volume":"113","author":"JR Taylor","year":"1990","unstructured":"Taylor JR, Elsworth JD, Roth RH, Sladek JR Jr, Redmond DE Jr (1990a) Cognitive and motor deficits in the acquisition of an object retrieval\/detour task in MPTP-treated monkeys. Brain 113(Pt 3):617\u2013637","journal-title":"Brain"},{"key":"3813_CR43","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0735-7044.104.4.564","volume":"104","author":"JR Taylor","year":"1990","unstructured":"Taylor JR, Roth RH, Sladek JR Jr, Redmond DE Jr (1990b) Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier. Behav Neurosci 104:564\u2013576","journal-title":"Behav Neurosci"},{"key":"3813_CR44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry Jr","year":"2003","unstructured":"Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821\u2013827","journal-title":"J Pharmacol Exp Ther"},{"key":"3813_CR45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.108.141788","volume":"327","author":"RL Thomas","year":"2008","unstructured":"Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA (2008) G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther 327:365\u2013374","journal-title":"J Pharmacol Exp Ther"},{"key":"3813_CR46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.33588\/rn.3605.2002416","volume":"36","author":"A Turon-Estrada","year":"2003","unstructured":"Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E, Garre-Olmo J, Lozano-Gallego M, Hernandez-Ferrandiz M, Fajardo-Tibau C, Morante-Munoz V, Vilalta-Franch J (2003) Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period. Rev Neurol 36:421\u2013424","journal-title":"Rev Neurol"},{"key":"3813_CR47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-012-2788-8","volume":"225","author":"JM Uslaner","year":"2013","unstructured":"Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, Pearson M, Vivian JA, Chang RK, Ray WJ, Kuduk SD, Wittmann M (2013) The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology (Berl) 225:21\u201330","journal-title":"Psychopharmacology (Berl)"},{"key":"3813_CR48","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","volume":"12","author":"AE Veroff","year":"1998","unstructured":"Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR (1998) Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the computerized neuropsychological test battery (CNTB). Alzheimer Dis Assoc Disord 12:304\u2013312","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3813_CR49","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","volume":"125","author":"J Watson","year":"1998","unstructured":"Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125:1413\u20131420","journal-title":"Br J Pharmacol"},{"key":"3813_CR50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.pharmtox.44.101802.121622","volume":"44","author":"J Wess","year":"2004","unstructured":"Wess J (2004) Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44:423\u2013450","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3813_CR51","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/S0024-3205(01)01057-8","volume":"68","author":"M Wienrich","year":"2001","unstructured":"Wienrich M, Meier D, Ensinger HA, Gaida W, Raschig A, Walland A, Hammer R (2001) Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci 68:2593\u20132600","journal-title":"Life Sci"},{"key":"3813_CR52","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(97)00075-4","volume":"80","author":"LS Wilkinson","year":"1997","unstructured":"Wilkinson LS, Dias R, Thomas KL, Augood SJ, Everitt BJ, Robbins TW, Roberts AC (1997) Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 80:717\u2013730","journal-title":"Neuroscience"},{"key":"3813_CR53","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjp.0702463","volume":"126","author":"MD Wood","year":"1999","unstructured":"Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol 126:1620\u20131624","journal-title":"Br J Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3813-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3813-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:12:39Z","timestamp":1747181559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3813-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,10]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3813-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,10]]}}}